CD274 and neoplasm: Prognostic tools such as the International Prognostic Index (IPI), alongside emerging biomarkers like circulating tumor DNA (ctDNA), soluble IL-2 receptor (sIL-2R), and PD-L1 expression, help stratify patient risk and guide therapy choices.